Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings

Table 2 Initial treatment, BMMSC treatment, and follow-up

Case	Initial treatment	MSCS treatment (IT/IA/IV)	3 months (CSF)	6 months (MRI/CSF)	12 months (MRI/CSF)	24 months (MRI/CSF)
1	Prednisone	IT+IA	Negative	MRI negative
2	Prednisone	IT+IA	Positive	MRI negative CSF negative
3	Prednisone Cytarabine	IT+IA	Negative	MRI better CSF negative
4	Prednisone	IT+IV after 1 year also IT+IA	Negative	MRI negative	MRI negative CSF negative	MRI negative CSF negative
5	Prednisone Cytarabine	IT+IV	Negative	MRI better	MRI unchanged CSF negative	MRI unchanged CSF negative
6	Prednisone, PB, levetiracetam	IT+IV	Negative	MRI unchanged
7	Prednisone, PB	IT+IV	Negative	MRI negative
8	Prednisone, PB, levetiracetam, cytarabine	IT+IV	Negative	MRI negative

ISSN: 1742-2094